User:David Canner/Sandbox good: Difference between revisions

LY294002, a competitive inhibitor of ATP binding in the PI3K kinase domain, was first discovered by scientists at Eli Lilly. Quercetin, Myricetin & Staurosporine are natural compounds which broadly inhibit protein kinases. Understanding how ATP binds to the ATP binding site <scene name='User:David_Canner/Sandbox_P/Inhibitor_main/4'>within the kinase domain</scene> of PI3Kγ and how various inhibitors prevent this interaction helps elucidate ways to develop effective, selective inhibitors. See p110γ bound to <scene name='User:David_Canner/Sandbox_P/Inhibitor_atp/5'>ATP</scene> ([[1e8x]]), <scene name='User:David_Canner/Sandbox_P/Inhibitor_wortmannin/7'>Wortmannin</scene> ([[1e7u]]), <scene name='User:David_Canner/Sandbox_P/Inhibitor_ly294002/2'>LY294002</scene> ([[1e7v]]), <scene name='User:David_Canner/Sandbox_P/Inhibitor_quer/2'>Quercetin</scene> ([[1e8w]]), <scene name='User:David_Canner/Sandbox_P/Inhibitor_staur/1'>Staurosporine</scene> ([[1e8z]]), <scene name='User:David_Canner/Sandbox_P/Inhibitor_myrice/1'>Myricetin</scene> ([[1e90]]).

====Tip #6: Whenever possible, try to illustrate points using same .pdb file to avoid "choppy" scene transitions. If unavoidable, include "reorienting" scenes which provide a view of the entire protein.====

__NOEDITSECTION__

__NOTOC__